Amylyx Pharmaceuticals Says 2026 Could Be “Transformative” Ahead of Avexitide Phase 3 Readout [Yahoo! Finance]
Amylyx Pharmaceuticals, Inc. (AMLX)
Company Research
Source: Yahoo! Finance
Amylyx Pharmaceuticals (NASDAQ:AMLX) executives outlined a slate of milestones they expect to shape the company's near-term trajectory during TD Cowen's 46th Annual Healthcare Conference, with co-CEOs Josh Cohen and Justin Klee emphasizing that 2026 could be “transformative” primarily due to a pivotal readout for avexitide in post-bariatric hypoglycemia (PBH). Avexitide Phase 3 timeline and near-term catalysts The company's lead program is avexitide, a GLP-1 receptor antagonist being developed for PBH. Management said the company initiated the LUCIDITY Phase 3 trial in 2025, describing it as the sixth clinical study of avexitide in PBH. The prior five PBH studies, the executives said, showed “very statistically significant, clinically meaningful reductions” in hypoglycemia and supported FDA Breakthrough Therapy designation. ? Defense Stocks Are Soaring—AeroVironment's Earnings Could Close the Gap These biotechs targeting multiple neurodegenerative diseases Amylyx announced
Show less
Read more
Impact Snapshot
Event Time:
AMLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMLX alerts
High impacting Amylyx Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AMLX
News
- Amylyx Pharmaceuticals Inc (AMLX) Q4 2025 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]Yahoo! Finance
- Amylyx Pharmaceuticals (AMLX) had its price target raised by HC Wainwright from $28.00 to $34.00. They now have a "buy" rating on the stock.MarketBeat
- Amylyx Refocuses On Avexatide As LUCIDITY Milestone Raises Stakes [Yahoo! Finance]Yahoo! Finance
- Amylyx Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
- Amylyx Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
AMLX
Earnings
- 3/3/26 - In-Line
AMLX
Sec Filings
- 3/4/26 - Form 4
- 3/4/26 - Form 4
- 3/4/26 - Form 4
- AMLX's page on the SEC website